Abstract:BackgroundThe success of clinical trials of selective B cell depletion in patients with relapsing multiple sclerosis (MS) indicates B cells are important contributors to peripheral immune responses involved in the development of new relapses. Such B cell contribution to peripheral inflammation likely involves antibody-independent mechanisms. Of growing interest is the potential that B cells, within the MS central nervous system (CNS), may also contribute to the propagation of CNS-compartmentalized inflammation in progressive (non-relapsing) disease. B cells are known to persist in the inflamed MS CNS and are more recently described as concentrated in meningeal immune-cell aggregates, adjacent to the subpial cortical injury which has been associated with progressive disease. How B cells are fostered within the MS CNS and how they may contribute locally to the propagation of CNS-compartmentalized inflammation remain to be elucidated.MethodsWe considered whether activated human astrocytes might contribute to B cell survival and function through soluble factors. B cells from healthy controls (HC) and untreated MS patients were exposed to primary human astrocytes that were either maintained under basal culture conditions (non-activated) or pre-activated with standard inflammatory signals. B cell exposure to astrocytes included direct co-culture, co-culture in transwells, or exposure to astrocyte-conditioned medium. Following the different exposures, B cell survival and expression of T cell co-stimulatory molecules were assessed by flow cytometry, as was the ability of differentially exposed B cells to induce activation of allogeneic T cells.ResultsSecreted factors from both non-activated and activated human astrocytes robustly supported human B cell survival. Soluble products of pre-activated astrocytes also induced B cell upregulation of antigen-presenting cell machinery, and these B cells, in turn, were more efficient activators of T cells. Astrocyte-soluble factors could support survival and activation of B cell subsets implicated in MS, including memory B cells from patients with both relapsing and progressive forms of disease.ConclusionsOur findings point to a potential mechanism whereby activated astrocytes in the inflamed MS CNS not only promote a B cell fostering environment, but also actively support the ability of B cells to contribute to the propagation of CNS-compartmentalized inflammation, now thought to play key roles in progressive disease.

Impact of Glatiramer Acetate on B Cell-Mediated Pathogenesis of Multiple Sclerosis

Glatiramer Acetate for the Treatment of Multiple Sclerosis: From First-Generation Therapy to Elucidation of Immunomodulation and Repair

The Role of B Cells and Antibodies in Multiple Sclerosis, Neuromyelitis Optica, and Related Disorders

Do Th2 Cells Mediate the Effects of Glatiramer Acetate in Experimental Autoimmune Encephalomyelitis?

Anti‐B cell therapies in multiple sclerosis

Memory B Cells in Multiple Sclerosis: Emerging Players in Disease Pathogenesis

B cells in multiple sclerosis - from targeted depletion to immune reconstitution therapies

Cd4(+)Cd25(+) Regulatory T Cells Contribute to the Therapeutic Effects of Glatiramer Acetate in Experimental Autoimmune Encephalomyelitis

Targeting B cells in multiple sclerosis

Impact of B cells to the pathophysiology of multiple sclerosis

Human central nervous system astrocytes support survival and activation of B cells: implications for MS pathogenesis

The Role of Antibodies in the Pathogenesis of Multiple Sclerosis

B-cell depletion therapy for multiple sclerosis

Cross-talk between B cells, microglia and macrophages, and implications to central nervous system compartmentalized inflammation and progressive multiple sclerosis

Circulating Memory B Cells in Early Multiple Sclerosis Exhibit Increased IgA+ Cells, Globally Decreased BAFF-R Expression and an EBV-Related IgM+ Cell Signature

Therapeutic developments in multiple sclerosis

Modulation Effects of Human Immature and Mature Dendritic Cells on Glatiramer Acetate Specific T Cell Lines in Vitro

A pathogenic and clonally expanded B cell transcriptome in active multiple sclerosis

Glatiramer Acetate Ameliorates Experimental Autoimmune Neuritis.

Enhanced and cross-reactive in vitro memory B cell response against Epstein-Barr virus nuclear antigen 1 in multiple sclerosis

Glatiramer acetate (Copaxone) therapy induces CD8(+) T cell responses in patients with multiple sclerosis